Steen came to Amarna with more than 30 years of experience from executive and non-executive positions in the life sciences industry, working with management, IP, technology, legal, finance and business strategy.
Prior to joining Amarna, Steen served as Chief Executive Officer (CEO) of the Nasdaq-listed vaccine development company ExpreS2ion Biotech Holding AB (SE) and its operative unit, ExpreS2ion Biotechnologies ApS (DK). He has also been Senior Vice President of preclinical R&D and Q of Allergopharma, a major player in allergy immune therapy (AIT) and the allergy business unit of Merck KGaA (DE). Further, he served as CEO of Nordic Vaccine (DK), a biotech company focusing on the development of non-invasive vaccination based on an integrated nanoparticle adjuvant and delivery platform. And finally, Steen held positions at the Danish biopharma companies Pharmexa, Novo Nordisk and ALK.
Steen holds a Ph.D. from the Technical University of Denmark combined with an Industrial Scientist Research Degree from the Danish “Academy of Technical Sciences”, and a M.Sc. degree in Biochemistry from the University of Copenhagen.
Over time Steen has authored/co-authored numerous patents and scientific articles published in (inter)-national peer-reviewed journals.
Peter de Haan PhD – Chief Scientific Officer & Co-founder
Peter has a virology background and has been active in R&D for more than twenty-five years.
Peter’s academic career started as a Virologist at the Wageningen University in The Netherlands, where he obtained his PhD in 1991. In 1991 he joined Novartis Seeds where he held several research management positions in the field of plant biotechnology. He is a co-founder of Phytovation B.V., formerly active in biopharmaceuticals and vaccine production, and of its subsidiary Viruvation B.V., which was active in developing therapeutic AIDS and HCV vaccines.
Throughout his career Peter has worked on applications of virus-associated technologies. He has a long-standing expertise in virology, molecular & cell biology, immunology and is highly experienced in molecular cloning activities, tissue culture of mammalian cells and production of (recombinant) virus particles in mammalian cell systems.
Peter is the (co-) author of more than fifty peer reviewed scientific articles. Next to this, he is the company’s intellectual property (IP) manager. Peter has a longstanding expertise with IP matter as (co-) inventor of more than twelve different awarded patents and patent applications.